New evidence supports the use of implantable cardioverter defibrillators (ICDs) to reduce all-cause mortality among primary prevention patients.

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1604, 2007-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antiarrhythmic Drugs in Patients with Implantable Cardioverter-Defibrillators

By Bollmann Andreas   Husser Daniela   Cannom David S.  

American Journal of Cardiovascular Drugs, Vol. 5, Iss. 6, 2005-01 ,pp. : 371-378

Adis International

Access to resources Recommend Favorite

Dertnatologic Electrosurgery in Patients with Implantable Cardioverter-Defibrillators and Pacemakers

By LeVASSEUR MAJOR JOHN G.   KENNARD CHARLES D.   FINLEY MAJOR ERIC M.   MUSE MAJOR ROGER K.  

Dermatologic Surgery, Vol. 24, Iss. 2, 1998-02 ,pp. : 233-240

Elsevier

Access to resources Recommend Favorite

Implantable cardioverter defibrillators

By Harris Stuart   Dhinoja Mehul  

Clinical Medicine, Vol. 7, Iss. 4, 2007-08 ,pp. : 397-400

Royal College Of Physicians

Access to resources Recommend Favorite

High-dose tocopherol increases all-cause mortality

By  

Inpharma, Vol. 1, Iss. 1464, 2004-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Aspirin reduces all-cause mortality in CAD

By  

Inpharma, Vol. 1, Iss. 1306, 2001-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite